title: Short- and long-term outcomes of intramyocardial implantation of autologous bone marrow-derived cells for the treatment of ischaemic heart disease.
abstract: Ischaemic heart disease remains a major cause of death in Japan. We have implanted autologous bone marrow-derived cells locally into the ischaemic region as a therapy in addition to coronary artery bypass grafting since 1999. We describe the outcomes of our cell therapy for ischaemic heart disease.
  
  
  
  Eleven patients underwent local implantation of bone marrow-derived cells into the ischaemic region during coronary artery bypass grafting. Clinical outcomes during the acute and chronic phases were recorded.
  
  
  
  In the acute phase, no adverse effects were observed. Left ventricular ejection fraction values were not significantly different before and after treatment. Seven of the 11 patients showed improved blood perfusion in the area of cell therapy 1 month after treatment. In the chronic phase, 5 of 11 patients exhibited improved regional blood flow 1 year after treatment. Overall survival at 1, 5 and 10 years was 100%, 83.3% and 83.3%, respectively. Freedom from major adverse cardiac and cerebrovascular events at 1, 5 and 10 years was 100%, 80.8% and 80.8%, respectively. Death from all causes or freedom from major adverse cardiac and cerebrovascular events at 1, 5 and 10 years was 100%, 64.6% and 64.6%, respectively.
  
  
  
  Local implantation of bone marrow-derived cells in patients with ischaemic heart disease is safe and feasible. Cell therapy is a therapeutic option for otherwise untreatable ischaemic heart disease.
authors.affiliation: Department Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kurazumi
authors.affiliation: Department of Clinical Pharmacology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.|Department of Anesthesia and Critical Care Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Fujita
authors.affiliation: Department Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Japan.
authors.forename: Tamami
authors.initials: T
authors.lastname: Nakamura
authors.affiliation: Department Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Japan.
authors.forename: Ryo
authors.initials: R
authors.lastname: Suzuki
authors.affiliation: Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Japan.
authors.forename: Masaya
authors.initials: M
authors.lastname: Takahashi
authors.affiliation: Department Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Japan.
authors.forename: Bungo
authors.initials: B
authors.lastname: Shirasawa
authors.affiliation: Department Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Japan.
authors.forename: Akihito
authors.initials: A
authors.lastname: Mikamo
authors.affiliation: Department Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Japan.
authors.forename: Kimikazu
authors.initials: K
authors.lastname: Hamano
mesh_terms: D016026:Bone Marrow Transplantation / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000601:surgery*; D009206:Myocardium; D013997:Time Factors; D014182:Transplantation, Autologous
keywords: Bone marrow mononuclear cells; Cell therapy; Ischaemic heart disease; Regenerative therapy